Table 1

Baseline patient characteristics

CharacteristicTXT q3w n = 335 (%)TXT qw n = 334 (%)MTZ q3w n = 337 (%)
Age (years)
 Median68.069.068.0
 Range42–9236–9243–86
Race
 Black8 (2.4)8 (2.4%)10 (3%)
 Caucasian312 (93.1%)312 (93.4%)312 (92.6%)
 Hispanic8 (2.4%)7 (2.1%)9 (2.7%)
 Oriental3 (0.9%)2 (0.6%)3 (0.9%)
 Other4 (1.2%)5 (1.5%)3 (0.9%)
Karnofsky PS (%)
>80293 (87.5)292 (87.4)290 (86.1)
<7042 (12.5)41 (12.3)47 (13.9)
 Missing01 (0.3)0
Staging at diagnosis
 I01 (0.3)1 (0.3)
 II54 (16.1)49 (14.7)56 (16.6)
 III60 (17.9)48 (14.4)51 (15.1)
 IV192 (57.3)193 (57.8)183 (54.3)
 Missing29 (8.7)43 (12.9)46 (13.6)
Gleason score
 2–419 (5.7)13 (3.9)23 (6.8)
 5–7123 (36.7)121 (36.2)119 (35.3)
 8–10105 (31.3)102 (30.5)93 (27.6)
 Missing88 (26.3)98 (29.3)102 (30.3)
Baseline PSA (ng/ml)
 Mean537404409
 Median114108123
 Range0.15–407400–167090.3–8022
  • Abbreviations: PS, performance status; PSA, prostate-specific antigen.